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Objective: We sought to identify whether there is an increased
risk of specific congenital anomalies after exposure to
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Methods: We performed a population-based case-malformed
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1496analyses were done for each nonsignal anomaly. The data set
included 76,249 registrations of congenital anomalies from 13
EUROmediCAT registries.
Results: Cleft palate (OR, 1.63; 95% CI, 1.05-2.52) and
gastroschisis (OR, 1.89; 95% CI, 1.12-3.20) had significantly
increased odds of exposure to first-trimester use of inhaled
b2-agonists compared with nonchromosomal control
registrations. Odds of exposure to salbutamol were similar.
NonsignificantORs of exposure to inhaledb2-agonists were found
for spina bifida, cleft lip, anal atresia, severe congenital heart
defects in general, or tetralogy of Fallot. None of the 4 literature
signals of exposure to inhaled steroids were confirmed (cleft
palate, cleft lip, anal atresia, and hypospadias). Exploratory
analyses found an association between renal dysplasia and
exposure to the combination of long-acting b2-agonists and
inhaled corticosteroids (OR, 3.95; 95% CI, 1.99-7.85).
Conclusions: The study confirmed increased odds of first-
trimester exposure to inhaled b2-agonists for cleft palate and
gastroschisis and found a potential new signal for renal
dysplasia associated with combined long-acting b2-agonists and
inhaled corticosteroids. Use of inhaled corticosteroids during
the first trimester of pregnancy seems to be safe in relation
to the risk for a range of specific major congenital anomalies.
(J Allergy Clin Immunol 2015;136:1496-502.)
Key words: Asthma medication, congenital anomalies, pregnancy,
first trimester exposure, inhaled b2-agonists, inhaled corticosteroids
Asthma is a chronic inflammatory respiratory disease reported
with increasing prevalence over the last decades.1 Increase in the
prevalence of asthma in pregnancy has also been reported.2,3 The
prevalence of asthma in pregnancy in Europe is estimated to be
4% to 8%.3-6
Medical treatment of asthma ismainly through use ofb2-agonists
for symptom relief (rescue treatment) and anti-inflammatory medi-
cations for reducing and preventing chronic inflammation in the air-
ways. Women becoming pregnant are recommended to continue
their medication during pregnancy, with a few exceptions.7-9
A stepwise approach in managing asthma during pregnancy is rec-
ommended.7-9 A British study based on prescriptions for asthma
medications found that 4.8% of pregnant women with asthma had
aprescription related toanexacerbationduringpregnancycompared
with 5.9% in the same season during the year before pregnancy.4
A meta-analysis concluded that maternal asthma is associated
with an increased risk of adverse maternal outcomes, including
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weight and preterm birth.10 Furthermore, the overall risk of
congenital anomalies is slightly increased with maternal asthma,
but there is lack of consensus concerning the effects ofmedication
versus the disease itself.11-13 Case-control studies have shown an
increased risk of specific congenital anomalies, such as facial
clefts, gastroschisis, and anal atresia, after first-trimester exposure
to asthma medications.14-16 Maternal asthma exacerbations dur-
ing the first trimester of pregnancy have been reported to be asso-
ciated with a 50% increased risk of congenital anomalies,17 and
exacerbations during pregnancy have also been associated with
other unfavorable pregnancy outcomes.18 Treatment decisions
need to balance the benefits for mother and baby of disease con-
trol against the risks related to medication use. Based on current
evidence, the general consensus is that uncontrolled asthma in-
creases perinatal risks, whereas well-controlled asthma reduces
these risks.7-9,11,12
The aim of this study is to contribute to the evidence base for
clinical decision making by investigating the increased risk of
specific congenital anomalies in relation to specific antiasthma
medications by using data from the EUROmediCAT database for
13 EUROCAT population-based congenital anomaly registries.
EUROmediCAT is a Seventh Framework Programme study
funded by the European Commission that aims to make more
systematic use of electronic health care databases in combination
with EUROCAT congenital anomaly data and build a European
system for the evaluation of medicine use in pregnancy in relation
to the risk of congenital anomalies.METHODS
Study design
This study has a case-malformed control study design19,20 using data from
EUROCAT population-based congenital anomaly registries contributing to
the EUROmediCAT database. The term ‘‘registration’’ is used for all notifica-
tions in the database. Cases are congenital anomalies that have been reported
as signals associated with asthmamedication in the literature, and control reg-
istrations are all other congenital anomalies divided into nonchromosomal and
chromosomal control registrations. An additional exploratory study was per-
formed within the nonchromosomal control group to identify any new signals
of congenital anomaly subgroups with raised risks.Study population and data
EUROCAT is a network of population-based registries collecting data on
congenital anomaly registrations among live births, fetal deaths of 20 weeks’
gestation or later, and terminations of pregnancy for fetal anomaly (TOPFAs).
Most registries include registrations diagnosed up to 1 year after birth.
Detailed descriptions of registries and the methodology have been published
previously.21,22 The congenital anomalies are coded with International Classi-
fication of Diseases, ninth revision, or International Classification of Diseases,
tenth revision, codes, and the codes are classified into standard EUROCAT
congenital anomaly subgroups (EUROCAT Guide 1.3; http://www.eurocat-
network.eu/content/EUROCAT-Guide-1.3.pdf).19 Registrations with only mi-
nor congenital anomalies according to a specific list are excluded from the
database (EUROCAT Guide 1.3).All registries taking part in the EUROmediCAT study (www.
EUROmediCAT.eu) were eligible for the study. A registry was included if
first-trimester exposure to asthma medication (Anatomical Therapeutic Chem-
ical [ATC] codeR03)was recorded for at least 3 per 1000 registrations for anyof
the 3 time intervals of 1995-1999, 2000-2004, and 2005-2010. With this crite-
rion set to exclude registrieswith lowascertainment of exposure, 13 registries in
12 countries were included for all or part of the period from, 1995-2010: Nor-
way, FunenCounty (Denmark),Mainz (Germany), NorthernNetherlands, Ant-
werp (Belgium), Paris (France), Vaud (Switzerland), Tuscany (Italy), Emilia
Romagna (Italy), Zagreb (Croatia), Malta, Wales (United Kingdom), and
Cork andKerry (Ireland). Only 2 registrieswere excluded because of low ascer-
tainment of exposures. The Emilia Romagna registry did not recordmedication
use for TOPFAs, and therefore only live births and late fetal deathswith congen-
ital anomalies were included from this registry.Literature review to identify ‘‘signals’’ to be tested
PubMed was used to search for English-language studies published
between January 1, 1990, and February 2, 2014, by using the search term
‘‘asthma’’ combined with any of the following: ‘‘congenital malformations,’’
‘‘congenital defects,’’ ‘‘birth defects,’’ ‘‘congenital abnormalities,’’ ‘‘congen-
ital anomalies,’’ and ‘‘pregnancy outcome.’’ The review is described in Fig 1.
The inclusion criteria of being a human epidemiologic controlled study of
congenital anomaly risk related to asthma medication were met by 68 publi-
cations. Nine original studies published statistically significant associations
between specific congenital anomalies and all or specific asthma medications,
which could be used as signals for this EUROmediCAT study; 2 were cohort
studies, and 7 were case-control studies (Table I).13-16,23-27Definition of case and control registrations
Registrations classified as genetic syndromes, teratogenic syndromes, or
skeletal dysplasias were excluded from the analysis. In EUROCAT registries
clinical geneticists are involved in the evaluation of most patients with
multiple malformation, dysmorphic features, or both. Therefore it is reason-
able to assume that all conditions with known cause, including midline
interruption overlap syndromes, such as DiGeorge syndrome and coloboma,
heart defect, atresia choanae, retarded growth and development, genital
abnormality, and ear abnormality (CHARGE) syndrome, are diagnosed,
coded, and excluded from the study. Registrations with unspecified abdominal
wall defects were also excluded because gastroschisis and omphalocele were
signals. All exclusions are presented in Fig 2.
Cases were defined as EUROCAT registrations with at least 1 of the signal
malformations: spina bifida, cleft palate, cleft lip with or without cleft palate,
severe congenital heart defects, tetralogy of Fallot, esophageal atresia, gastro-
schisis, omphalocele, hypospadias, and anorectal atresia, stenosis, or both.
Registrations with Pierre Robin sequence were excluded from the cleft palate
and cleft lip with or without cleft palate case groups because the cleft palate in
these cases is part of a sequence andmight have a separate cause. Pierre Robin is
a sequence derived from micrognathia (hypoplastic mandible), leading to
displacement of the tongue and obstructing the closure of the palate. It might be
part of a genetic syndrome but otherwise considered an isolated malformation
(http://www.eurocat-network.eu/content/EUROCAT-Guide-1.3.pdf).
Similarly, for the exploratory analysis, registrationswith bladder exstrophy,
epispadias, prune belly, or the posterior urethral valve were excluded from the
hydronephrosis case group because the hydronephrosis in these registrations
was assumed to be secondary to the underlying anomalies.
Two control groups were used: a group of control subjects with
chromosomal anomalies and 1 group comprised of other EUROCAT
registrations with nongenetic, nonsignal congenital anomalies. When
analyzing hypospadias as an outcome, male control subjects only were used.Exposure
Information on medication exposure in the first trimester of pregnancy was
obtained mainly from obstetric/midwife records created before birth. Addi-
tional data sources available for some registrieswere themedical records of the
FIG 1. Flowchart describing the literature review.
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interviews before or after birth. In the northern Netherlands prescription data
were used as an additional data source. For Norway, the only data available for
first-trimester exposure were prescription redemption records. For all regis-
tries, the first trimester of pregnancywas defined as the period from the first day
of the last menstrual period to the end of gestational week 12.
Exposure was defined as use of asthma medication (ATC code R03) in the
first trimester of pregnancy. Exposure was grouped into asthma medication
classes based on 5-digit ATC codes: inhaled b2-agonists, inhaled corticoste-
roids, and all asthmamedications (Table II). For the Paris registry, mode of de-
livery for b2-agonists was unknown. Where ATC codes for asthma
medications were given as 3- or 4-digit codes, the registries were asked
whether the medication could be identified in more detail, and if this was
not possible, the registrationwas excluded to avoid exposuremisclassification.
Further excluded were registrations in which the mother was coded as taking
an unspecifiedmedication, as having asthmawith no asthmamedication use in
the first trimester recorded, or as having unknown timing of the asthma medi-
cation (Fig 2). Finally, mothers recorded as using antiepileptics or antidia-
betics or as having epilepsy or diabetes were excluded.
Study power
Preliminary power analyses assuming a control group size of 50,000 and an
overall exposure rate of 2% showed 80% power of detecting an odds ratio
(OR) of 1.72 that was significant at the 5% level for an anomaly with 1000
cases. Looking at specific asthma medication groups with exposure rates of1% or at rarer anomalies with 500 cases, we have 80% power to detect at the
5% level an OR of 2.05.
Statistical analyses
ORs of exposure to each of the main groups of asthma medication were
calculated for each of 10 signal anomalies compared with nonchromosomal,
nonsignal anomalies as control registrations. Adjusted ORs of exposure were
calculated by using logistic regression with random effects for registry using
the SAS 9.3 GLIMMIX procedure. ORs were also adjusted for maternal age
(categorized as <25 years, 25-29 years, 30-34 years, 35-39 years, and >_40
years), and analyses for inhaled b2-agonists were adjusted for use of inhaled
corticosteroids and vice versa. Sensitivity analyses were adjustment for
first-trimester use of systemic corticosteroids (ATC code H02AB), adjustment
for period, and restriction to isolated anomalies.
In the exploratory analysis within the nonchromosomal control group, the
ORs of each of 62 EUROCAT congenital anomaly subgroups of exposure to
asthma medications in general or to each of the 3 asthma medication classes
were calculated by using all other nonchromosomal registrations in this group
as control registrations. Adjustment was made for maternal age and registry as
in themain analysis.Only subgroupswith at least 5 exposed cases arepresented.
RESULTS
The study included 76,249 registrations of congenital anom-
alies in the 13 registries during the years 1995-2010. After
TABLE I. Literature signals for specific congenital anomalies after exposure to asthma medications
Congenital anomaly Medication type Exposed cases OR 95% CI Adjusted OR 95% CI Reference
Spina bifida Asthma medication 12 4.41 1.61-12.1 3.25* 1.29-8.16 Blais et al, 201013
Cleft lip b2-Agonists 20 1.77 1.08-2.88 Munsie et al, 2011
14
Cleft lip Albuterol 18 1.79 1.07-2.99
Cleft palate only Albuterol 25 1.665 1.06-2.58
Cleft lip with/without cleft palate Systemic corticosteroids 7 2.59 1.18-5.67 Pradat et al, 200323
Major cardiac Long acting b2-agonists 7 2.38§ 1.11-5.10 Eltonsy et al, 2011
26
Severe CHD b2-Agonists 22 2.20 1.05-4.61 Lin et al 2009
25
Tetralogy of Fallot Asthma medication 19 1.66 1.05-2.62 K€allen et al, 200724
Esophageal atresia, isolated b2-Agonists 10 2.39k 1.23-4.66 Lin et al, 201216
Anorectal atresia Anti-inflammatory 10 2.12k 1.09-4.12 Lin et al, 201216
Gastroschisis b2-Agonists 17 1.94 1.14-3.29 2.06{ 1.19-3.59 Lin et al, 200815
Omphalocele b2-Agonists and anti-inflammatory 4 4.13k 1.43-11.95 Lin et al, 201216
Hypospadias Corticosteroids, any route 39 1.6 1.1-2.5 1.3# 0.8-2.0 Carmichael et al 200927
CHD, Congenital heart defect.
*Adjusted for maternal socioeconomic variables, pregnancy-related variables, and maternal chronic conditions.
Adjusted for maternal age, race, ethnicity, education, alcohol consumption, smoking, marijuana use, use of folic acid, vasoactive medication use, and infant’s sex.
Adjusted for caffeine use, fever, vitamin use, trihalomethane exposure, maternal age, race, ethnicity, and body mass index.
§Adjusted for sociodemographic variables, maternal and fetal characteristics, and asthma-related variables (comedications and others).
kAdjusted for infant’s sex, maternal age, body mass index, parity, race/ethnicity, education, alcohol use, smoking, folic acid, fever, cocaine use, and asthma medications.
{Adjusted for maternal age, ethnicity, education, smoking, use of other vasoactive drugs, and use of folic acid.
#Education, race/ethnicity, maternal age, parity, folic acid, smoking, subfertility, and study area.
FIG 2. Flowchart describing inclusions and exclusions for the signal testing
analysis. For exploratory analysis, registrations exposed to unspecified
antiasthma medications were included.
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70,205 (92%). Of these, 16,803 had a congenital anomaly within
one of the 10 signal congenital anomaly subgroups. The nonchro-
mosomal control group included 43,824 registrations, and the
chromosomal control group included 9,578 registrations.
Overall, 1,301 registrations (1.85% of all registrations) were
exposed to 1 or more asthma medications defined by the ATC
code R03 (Table II). Inhaled b2-agonists were the most common
medication used, with an exposure rate of 1.36%. In the signal
groups 356 (2.12%) registrations were exposed to 1 or more
asthma medications. In the nonchromosomal control group 809
(1.85%) were exposed, and in the chromosomal control group
136 (1.42%) were exposed to 1 or more asthma medications.The results of the signal analysis are presented in Table III
(adjusted OR). For inhaled b2-agonists, 2 signals were confirmed:
cleft palate and gastroschisis. For cleft palate, the OR of exposure
to b2-agonists was 1.63 (95% CI, 1.05-2.52) compared with
nonchromosomal control registrations and 1.97 (95% CI, 1.19-
3.25) compared with chromosomal control registrations. For gas-
troschisis, the OR was 1.89 (95% CI, 1.12-3.20) compared with
nonchromosomal control registrations and 3.04 (95% CI, 1.53-
6.06) compared with chromosomal control registrations. Salbuta-
mol was the most frequently used inhaled b2-agonist (818/953
[86%]). The OR of exposure to inhaled salbutamol was similar
to that to inhaled b2-agonists in general (cleft palate: OR, 1.63;
95% CI 1.02-2.60; gastroschisis: OR, 2.01; 95% CI, 1.18-3.44)
compared with nonchromosomal control registrations. For cleft
palate and gastroschisis, the OR of exposure to b2-agonists in
general (inhaled, systemic, and unknown mode of delivery) re-
mained the same (see this article’s Online Repository at www.
jacionline.org).
None of the 4 signals for inhaled corticosteroids (cleft lip and
palate, cleft palate, anal atresia/stenosis, and hypospadias) were
confirmed. The odds of exposure to asthma medication in general
for anal atresia/stenosis was significantly increased (OR, 1.64;
95% CI, 1.08-2.51). The ORs of exposure to b2-agonists and
inhaled corticosteroids for anal atresia/stenosis were both nonsig-
nificantly increased (Table III).
Sensitivity analysis was performed by adjusting for use of
systemic steroids (asthma severity), period (5-year intervals), and
restricting to isolated anomalies only and showed almost no
difference in the ORs (see this article’s Online Repository).
In the exploratory analysis using nonsignal EUROCAT sub-
groups, there were 3 statistically significant positive associations
at the 5% level of significance and 1 positive association at the 1%
level (Table IV). The 3 associations at the 5% significance level
were clubfoot (OR, 1.38; 95% CI, 1.08-1.76) for exposure to
any asthma medications and encephalocele and Pierre Robin
sequence for exposure to inhaled b2-agonists (OR, 2.24 [95%
CI, 1.04-4.80] and 2.65 [95% CI, 1.15-6.09], respectively). The
TABLE II. Asthma medications and number of exposed among all registrations, 13 registries, 1995-2010
ATC codes
All registrations
Exposed to 1
asthma
medication only
Exposed to 2
asthma
medications
Exposed to >_3
asthma
medications
No. Percent No. Percent No. Percent No. Percent
Total no. of registrations 70,205 100
Exposed to asthma medications R03 1,301 1.85 806 1.15 452 0.64 43 0.06
Inhaled b2-agonists R03AC 953 1.36 507 0.72 408 0.58 38 0.05
Short-acting b2-agonists R03AC02-R03AC07 924 1.32 498 0.71 389 0.55 37 0.05
Long acting b2-agonists R03AC12-R03AC13 47 0.07 10 0.01 31 0.04 6 0.01
Systemic b2-agonists R03CC 8 0.01 4 0.01 2 0.00 2 0.00
b2-Agonists, mode of delivery unknown R03CC* 37 0.05 22 0.03 13 0.02 2 0.00
Inhaled corticosteroids R03BA 533 0.76 170 0.24 337 0.48 26 0.04
Combination b2-agonists and inhaled corticosteroids R03AK 191 0.27 94 0.13 77 0.11 20 0.03
Anticholinergic inhaled medications R03BB 11 0.02 2 0.00 5 0.01 4 0.01
Theophyllines R03DA 9 0.01 2 0.00 3 0.00 4 0.01
Leukotriene receptor antagonists R03DC 12 0.02 2 0.00 5 0.01 5 0.01
Cromoglycate and nedocromil R03BC 10 0.01 3 0.00 4 0.01 3 0.00
*Medication could not be confirmed as being for systemic use.
TABLE III. Results of the signal analysis: OR for anomaly with exposure to the signal medications compared with no exposure in
nonchromosomal and chromosomal control registrations
Control group
Any asthma medication Inhaled b2-agonists, ATC code R03AC
Inhaled corticosteroids, ATC code
R03BA
Nonchromosomal Chromosomal Nonchromosomal Chromosomal Nonchromosomal Chromosomal
Controls 43,824 9,578 43,824 9,578 43,824 9,578
Exposed controls 809 136 592 97 349 51
Total
cases
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Any signal
anomaly
16,803 356 1.15 (1.01-1.30) 1.42 (1.15-1.76) 264 1.23 (1.05-1.46) 1.46 (1.10-1.93) 133 0.85 (0.68-1.07) 1.01 (0.68-1.49)
Spina bifida 1,194 20 0.88 (0.56-1.38) 1.06 (0.66-1.72) 17 0.90 (0.52-1.56) 1.39 (0.74-2.60) 7 1.46 (0.63-3.38) 0.67 (0.26-1.74)
Cleft palate 1,392 39 1.53 (1.10-2.12) 1.68 (1.15-2.45) 28 1.63 (1.05-2.52) 1.97 (1.19-3.25) 13 0.83 (0.44-1.57) 0.95 (0.46-1.97)
Cleft lip with/
without
cleft palate
2,402 51 1.19 (0.89-1.59) 1.34 (0.95-1.90) 39 1.32 (0.91-1.92) 1.57 (0.98-2.52) 22 0.98 (0.60-1.61) 1.15 (0.61-2.16)
Severe CHD 4,738 87 1.00 (0.80-1.25) 1.21 (0.91-1.60) 64 1.21 (0.91-1.61) 1.38 (0.95-2.02) 27 0.61 (0.40-0.94) 0.74 (0.43-1.29)
Tetralogy of
Fallot
730 10 0.77 (0.41-1.44) 0.83 (0.43-1.60) 9 1.29 (0.63-2.62) 1.54 (0.70-3.38) 3 0.43 (0.13-1.45) 0.48 (0.13-1.78)
Esophageal
atresia
648 12 1.09 (0.61-1.95) 1.67 (0.96-2.90) 7 1.31 (0.59-2.90) 1.68 (0.72-3.94) 2 0.33 (0.08-1.43) 0.40 (0.09-1.89)
Gastroschisis 615 22 1.61 (1.04-2.50) 1.76 (1.03-2.98) 19 1.89 (1.12-3.20) 3.04 (1.53-6.06) 5 0.59 (0.22-1.60) 0.33 (0.10-1.11)
Omphalocele 467 11 1.36 (0.74-2.49) 1.18 (0.65-2.15) 9 1.52 (0.69-3.33) 1.76 (0.74-4.20) 5 1.08 (0.38-3.06) 1.26 (0.39-4.05)
Hypospadias 5097 107 1.06 (0.86-1.32) 1.60 (1.11-2.31) 76 1.03 (0.77-1.37) 1.31 (0.82-2.11) 43 0.99 (0.68-1.45) 1.32 (0.68-2.55)
Anal atresia/
stenosis
772 23 1.64 (1.08-2.51) 2.04 (1.30-3.20) 18 1.51 (0.85-2.68) 1.78 (0.92-3.44) 12 1.49 (0.74-3.02) 1.66 (0.73-3.77)
Analyses were adjusted for registry and maternal age. Analyses of b2-agonists were adjusted for use of corticosteroids and vice versa. Italics denote results for an anomaly for
which there is not a signal for inhaled b2-agonists or antiasthma medication in general but for which there exists a signal for corticosteroids or vice versa.
Boldface denotes associations significant at the 5% level.
CHD, Congenital heart defect.
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dysplasia for exposure to the combination of long-acting b2-ago-
nists and inhaled corticosteroids (OR, 3.96; 95% CI, 1.99-7.87).DISCUSSION
In this large population-based case-malformed control study
combining data from 13 congenital anomaly registers throughout
Europe, we confirmed previous findings that cleft palate andgastroschisis are associated with first-trimester exposure tob2-ag-
onists. We did not confirm any of the signals for specific congen-
ital anomalies with first-trimester exposure to inhaled
corticosteroids.
Our finding of increased odds of exposure to inhaled b2-ago-
nists (nonchromosomal control registrations: OR, 1.63; 95% CI,
1.05-2.52) for cleft palate is consistent with 2 previous studies us-
ing different methodologies. A case-control study of cleft palate
found significantly increased odds of exposure to albuterol
TABLE IV. Exploratory analysis for nonsignal congenital anomaly subgroups
All nonsignal, nonchro-
mosomal registrations Total cases
Any asthma medication Inhaled b2-agonists Inhaled steroids
Long-acting b2-agonists
and inhaled steroids
No. Adjusted OR* (95% CI) No. Adjusted OR* (95% CI) No. Adjusted OR* (95% CI) No. Adjusted OR* (95% CI)
Anencephalus 826 17 1.06 (0.65-1.73) 13 1.03 (0.59-1.80) 6 0.9 (0.40-2.04) 5 2.13 (0.87-5.23)
Encephalocele 223 7 1.70 (0.80-3.64) 7 2.24 (1.04-4.80) <5 <5
Hydrocephalus 1,205 21 1.05 (0.68-1.63) 14 0.96 (0.56-1.64) 8 0.97 (0.48-1.97) <5
Microcephaly 459 8 0.81 (0.40-1.64) 8 1.01 (0.50-2.05) <5 <5
Congenital heart defects 13,860 242 0.90 (0.77-1.05) 183 0.93 (0.78-1.11) 107 0.95 (0.76-1.20) 37 0.85 (0.58-1.25)
VSD 8,227 136 0.92 (0.76-1.11) 100 0.95 (0.77-1.18) 61 0.96 (0.72-1.27) 20 0.82 (0.51-1.33)
ASD 3,228 70 1.07 (0.83-1.37) 56 1.11 (0.84-1.47) 23 0.83 (0.54-1.27) 8 0.82 (0.40-1.68)
Pulmonary valve stenosis 1,118 27 1.14 (0.77-1.68) 19 1.03 (0.65-1.63) 15 1.34 (0.79-2.27) <5
PDA as only CHD in term
infants
843 15 0.81 (0.48-1.37) 10 0.70 (0.37-1.31) 5 0.78 (0.32-1.89) 6 1.80 (0.78-4.15)
Duodenal atresia or
stenosis
206 5 1.34 (0.55,3.28) <5 <5 <5
Hirschsprung disease 352 5 0.73 (0.30-1.79) <5 <5 <5
Diaphragmatic hernia 608 7 0.63 (0.30-1.33) 6 0.78 (0.35-1.75) <5 <5
Renal dysplasia 965 23 1.40 (0.92-2.14) 15 1.21 (0.72-2.04) 6 0.81 (0.36-1.82) 9 3.96 (1.99-7.87)
Congenital
hydronephrosis
3,367 74 1.23 (0.96-1.57) 58 1.30 (0.99-1.72) 34 1.33 (0.93-1.91) 9 0.98 (0.49-1.93)
Posterior urethral valve/
prune belly
350 9 1.44 (0.74-2.81) 8 1.74 (0.85-3.53) <5 <5
Limb reduction 1,198 26 1.22 (0.82-1.81) 21 1.37 (0.88-2.13) 11 1.15 (0.63-2.11) <5
Club foot–talipes
equinovarus
2,857 74 1.38 (1.08-1.76) 48 1.22 (0.91-1.65) 28 1.16 (0.78-1.71) 12 1.37 (0.75-2.48)
Hip dislocation and/or
dysplasia
3,669 79 1.00 (0.78-1.27) 66 1.13 (0.86-1.48) 30 0.80 (0.54-1.18) 11 0.87 (0.46-1.65)
Polydactyly 2,366 40 0.95 (0.69-1.31) 26 0.87 (0.58-1.29) 21 1.14 (0.73-1.78) 8 1.21 (0.59-2.48)
Syndactyly 1,189 26 1.19 (0.80-1.77) 16 1.00 (0.60-1.65) 14 1.50 (0.87-2.57) <5
Craniosynostosis 601 6 0.51 (0.23-1.14) <5 <5 <5
Congenital skin disorders 500 8 0.81 (0.40-1.64) 5 0.68 (0.28-1.65) <5 <5
Pierre Robin sequence 128 6 2.10 (0.92-4.79) 6 2.65 (1.15-6.09) <5 <5
Anomaly subgroups with less than 5 exposures are not presented.
Boldface denotes associations significant at the 5% level.
ASD, Atrial septal defect; CHD, Congenital heart defect; VSD, ventricular septal defect.
*Adjusted for registry and maternal age.
Significant at the 1% level.
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line significant odds of exposure to b2-agonists combined (OR,
1.53; 0.99-2.37).14 A cohort study of cleft palate from Sweden
found increased odds of exposure to any asthma medication
with the majority of women being exposed to inhaled b2-agonists
(OR, 1.45; 95% CI, 1.06-1.98).28 In both studies it is not clear
whether it is the asthma medication or the underlying asthma
that is responsible for the cleft palate. In our study the lack of as-
sociation with inhaled corticosteroids suggests that if it is the un-
derlying asthma, it is not the type of underlying asthma treated by
corticosteroids.
Our case-malformed control study showing increased odds of
exposure to inhaled b2-agonists and salbutamol for gastroschisis
specifically supports a previous case-control study15 that found
increased odds (adjusted OR, 2.06; 95% CI, 1.19-3.59) of expo-
sure to bronchodilators in general.
We were not able to confirm the remaining 8 literature signals
(spina bifida, cleft lip with or without cleft palate, severe
congenital heart defect, tetralogy of Fallot, esophageal atresia,
omphalocele, hypospadias, and anal atresia/stenosis), although
we found an OR of greater than 1 for most b2-agonist exposures,
which was not statistically significant. For inhaled steroids, the
ORs in general were closer to 1.The exploratory analysis identified only 1 association at the 1%
significance level, namely renal dysplasia and exposure to the
combination product of inhaled long-acting b2-agonists and cor-
ticosteroids. Furthermore, there were 3 positive associations at a
5% significance level. We think the observation of a 3-fold in-
crease for renal dysplasia in odds of exposure needs attention.
The OR for Pierre Robin sequence of exposure to inhaled b2-ag-
onists was higher than for cleft palate without Pierre Robin
sequence (OR, 2.67 [95% CI, 1.16-6.13] and 1.63 [95% CI,
1.05-2.52], respectively). The cause for Pierre Robin sequence
is thought to be heterogeneous,29 and this finding suggests that
some Pierre Robin sequences share etiologic factors with cleft
palate.
For the other findings, they might be explained by the large
number of comparisons that have been performed, and therefore
these associations could be chance findings, although this could
be confirmed in independent data sets.
Although we have found increased odds of cleft palate and
gastroschisis after exposure to b2-agonists, the excess risk for the
individual woman is low. The nonchromosomal prevalence of
these 2 congenital anomalies in the EUROCAT registries is 8 to
9 per 10,000 births.21 Even with a 5-fold increased risk, the risk
for the individual pregnancy is still less than 1 in 100. This is
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much greater than these specific risks.
It is reassuring that we did not find any increased risk for
specific congenital anomalies of exposure to inhaled steroids in
the signal testing analysis. Both maternal asthma and asthma
exacerbation during the first trimester of pregnancy have been
found to increase the risk of congenital anomalies.12,17 Further
asthma exacerbations during pregnancy have been associated
with other unfavorable pregnancy outcomes for both the mother
and infant.18 Use of prophylactic inhaled steroids seems to be
the best solution for treatment of asthma in pregnancy to prevent
asthma exacerbations and to reduce the need for b2-agonists.
The strength of the present study is the ability to combine
population-based data from a number of congenital anomaly
registers throughout Europe, all of which use the same methods
for case registration and classification and all of which have
information about maternal medication use in pregnancy. This
ensures an adequate number of exposed cases to evaluate specific
congenital anomalies, although power might still be too low to
study specific medications in relation to some specific anomalies.
The congenital anomaly registers all use multiple data sources to
collect information about congenital anomaly cases for all types
of birth outcomes, including TOPFAs, in geographically defined
residential populations. A common guide for classification of
congenital anomalies is used by all registers, ensuring similar
definitions for all cases. The main limitation is the information
about medication exposure, which might be less specific accord-
ing to both the dosage and timing of exposure. For one registry,
medication exposure was available for births but not for TOPFAs.
For another registry, the exposure data were based on information
from a prescription database. Therefore we do not know whether
these mothers took the medication they picked up at the
pharmacy. Most importantly, although the fetuses were exposed
to asthma medication, we cannot know whether it was the
medication that caused the congenital anomalies or whether it
was the maternal asthma because different types of antiasthma
medications are used for different severities of asthma. There was
limited information on potential confounding factors, but because
registries collect standardized data on congenital anomalies for
both exposed and unexposed cases and information onmedication
was obtained prospectively, the potential for bias is reduced.
Although this study included more than 70,000 registrations of
congenital anomalies in the 13 registries during the years 1995-
2010, the power to detect any individual associations was low.
Therefore it is important to continue European collaboration to be
able to improve the detection of such associations in future.
Clinical implications: Use of prophylactic inhaled steroids
seems to be the best solution for treatment of asthma in preg-
nancy to prevent asthma exacerbations and to reduce the
need for b2-agonists.REFERENCES
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TABLE E1. Combination treatments and all asthma medications
Control group
Combination treatments Any asthma medications
Nonchromosomal Chromosomal Nonchromosomal Chromosomal
Controls 43,824 9,578 43,824 9,578
Exposed controls 131 26 809 136
Total
cases
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Any signal anomaly 16,803 60 1.09 (0.79-1.49) 1.09 (0.65-1.83) 356 1.15 (1.01-1.30) 1.42 (1.15-1.76)
Spina bifida 1,194 3 0.84 (0.26-2.69) 1.18 (0.38-3.69) 20 0.88 (0.56-1.38) 1.06 (0.66-1.72)
Cleft palate 1,392 3 0.57 (0.18-1.83) 0.56 (0.16-1.97) 39 1.53 (1.10-2.12) 1.68 (1.15-2.45)
Cleft lip with/without
cleft palate
2,402 8 0.89 (0.43-1.86) 0.76 (0.32-1.83) 51 1.19 (0.89-1.59) 1.34 (0.95-1.90)
Severe CHD 4,738 19 1.33 (0.81-2.18) 1.18 (0.61-2.27) 87 1.00 (0.80-1.25) 1.21 (0.91-1.60)
Tetralogy of Fallot 730 2 0.98 (0.23-4.06) 1.04 (0.23-4.72) 10 0.77 (0.41-1.44) 0.83 (0.43-1.60)
Esophageal atresia 648 3 1.69 (0.52-5.48) 3.63 (1.26-10.42) 12 1.09 (0.61-1.95) 1.67 (0.96-2.90)
Gastroschisis 615 4 1.77 (0.61-5.13) 1.99 (0.57-6.98) 22 1.61 (1.04-2.50) 1.76 (1.03-2.98)
Omphalocele 467 0 11 1.36 (0.74-2.49) 1.18 (0.65-2.15)
Hypospadias 5097 20 1.26 (0.75-2.10) 2.75 (0.99-7.63) 107 1.06 (0.86-1.32) 1.60 (1.11-2.31)
Anal atresia/stenosis 772 3 1.00 (0.31-3.24) 1.36 (0.43-4.28) 23 1.64 (1.08-2.51) 2.04 (1.30-3.20)
Analyses were adjusted for center and maternal age, and combination treatment was adjusted for use of short-acting b2-agonists. All asthma medications groups encompasses
medications with ATC code R03, and combination treatments are medications with ATC code R03AK or a long-acting b2-agonist in combination with inhaled steroids.
Boldface denotes associations significant at the 5% level.
CHD, Congenital heart defect.
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TABLE E2. Salbutamol and b2-agonists in general
Control group
Salbutamol, ATC code R03AC02 b2-Agonists in general, ATC codes R03AC & R03CC
Nonchromosomal Chromosomal Nonchromosomal Chromosomal
Controls 43,824 9,578 43,824 9,578
Exposed controls 504 85 596 97
Total
cases
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Any signal anomaly 16,803 229 1.26 (1.06-1.50) 1.46 (1.09-1.96) 265 1.23 (1.04-1.45) 1.47 (1.11-1.94)
Spina bifida 1,194 15 1.15 (0.65-2.04) 1.28 (0.67-2.43) 17 1.10 (0.64-1.90) 1.30 (0.70-2.43)
Cleft palate 1,392 24 1.63 (1.02-2.60) 1.62 (0.95-2.77) 28 1.62 (1.04-2.50) 1.70 (1.03-2.79)
Cleft lip with/without
cleft palate
2,402 33 1.36 (0.91-2.03) 1.45 (0.89-2.38) 39 1.31 (0.90-1.91) 1.39 (0.87-2.21)
Severe CHD 4,738 53 1.17 (0.85-1.59) 1.17 (0.79-1.73) 64 1.20 (0.90-1.60) 1.23 (0.85-1.78)
Tetralogy of Fallot 730 8 1.37 (0.64-2.90) 1.38 (0.61-3.13) 9 1.27 (0.62-2.60) 1.36 (0.62-2.95)
Esophageal atresia 648 6 1.41 (0.60-3.29) 1.49 (0.60-3.69) 8 1.51 (0.72-3.17) 1.69 (0.76-3.75)
Gastroschisis 615 18 2.01 (1.18-3.44) 2.81 (1.40-5.64) 19 1.89 (1.11-3.19) 2.92 (1.48-5.77)
Omphalocele 467 9 1.92 (0.89-4.15) 1.62 (0.75-3.52) 10 1.75 (0.83-3.67) 1.57 (0.75-3.32)
Hypospadias 5,097 68 1.11 (0.82-1.49) 1.33 (0.81-2.19) 76 1.02 (0.76-1.35) 1.27 (0.79-2.04)
Anal atresia/stenosis 772 16 1.58 (0.87-2.88) 1.54 (0.78-3.04) 18 1.49 (0.84-2.66) 1.53 (0.79-2.93)
Analyses were adjusted for center, maternal age, and use of inhaled corticosteroids.
CHD, Congenital heart defect.
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TABLE E3. Crude ORs
Control group
Inhaled b2-agonists, ATC code R03AC Inhaled corticosteroids, ATC code R03BA
Nonchromosomal Chromosomal Nonchromosomal Chromosomal
Controls 43,824 9,578 43,824 9,578
Exposed controls 592 97 349 51
Total
cases
Exposed
cases
Crude OR
(95% CI)
Crude OR
(95% CI)
Exposed
cases
Crude OR
(95% CI)
Crude OR
(95% CI)
Any signal anomaly 16,803 264 1.17 (1.01-1.35) 1.56 (1.23-1.97) 133 0.99 (0.81-1.21) 1.49 (1.08-2.06)
Spina bifida 1,194 17 1.05 (0.65-1.71) 1.31 (0.78-2.21) 7 0.73 (0.35-1.56) 1.03 (0.46-2.27)
Cleft palate 1,392 28 1.50 (1.02-2.20) 1.81 (1.18-2.76) 13 1.17 (0.67-2.05) 1.59 (0.86-2.92)
Cleft lip with/without
cleft palate
2,402 39 1.21 (0.87-1.67) 1.46 (1.00-2.12) 22 1.15 (0.75-1.78) 1.56 (0.94-2.57)
Severe CHD 4,738 64 1.00 (0.77-1.30) 1.32 (0.97-1.81) 27 0.71 (0.48-1.06) 1.27 (0.81-1.98)
Tetralogy of Fallot 730 9 0.91 (0.47-1.77) 1.06 (0.53-2.10) 3 0.51 (0.16-1.61) 0.67 (0.21-2.15)
Esophageal atresia 648 7 0.80 (0.38-1.69) 0.95 (0.44-2.06) 2 0.39 (0.10-1.55) 0.52 (0.13-2.12)
Gastroschisis 615 19 2.33 (1.46-3.70) 3.03 (1.84-5.00) 5 1.02 (0.42-2.48) 1.49 (0.59-3.75)
Omphalocele 467 9 1.44 (0.74-2.79) 1.37 (0.71-2.64) 5 1.35 (0.55-3.27) 1.29 (0.51-3.23)
Hypospadias 5,097 76 1.08 (0.84-1.39) 1.59 (1.08-2.34) 43 1.04 (0.74-1.45) 1.80 (1.06-3.06)
Anal atresia/stenosis 772 18 1.74 (1.08-2.80) 2.28 (1.39-3.75) 12 1.97 (1.10-3.51) 3.29 (1.81-5.98)
CHD, Congenital heart defect.
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TABLE E4. Effect of medications when not adjusted for other medication use
Control group
Inhaled b2-agonists, ATC code R03AC Inhaled corticosteroids, ATC code R03BA
Nonchromosomal Chromosomal Nonchromosomal Chromosomal
Controls 43,824 9,578 43,824 9,578
Exposed controls 592 97 349 51
Total
cases
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Any signal anomaly 16,803 264 1.17 (1.01-1.35) 1.46 (1.13-1.88) 133 0.97 (0.80-1.19) 1.27 (0.89-1.80)
Spina bifida 1,194 17 0.98 (0.60-1.59) 1.13 (0.66-1.94) 7 0.73 (0.35-1.56) 0.81 (0.36-1.83)
Cleft palate 1,392 28 1.53 (1.04-2.25) 1.65 (1.06-2.57) 13 1.14 (0.65-1.99) 1.28 (0.67-2.43)
Cleft lip with/without
cleft palate
2,402 39 1.31 (0.94-1.83) 1.44 (0.97-2.15) 22 1.16 (0.75-1.79) 1.38 (0.81-2.35)
Severe CHD 4,738 64 1.03 (0.80-1.34) 1.22 (0.88-1.70) 27 0.69 (0.46-1.02) 1.10 (0.68-1.77)
Tetralogy of Fallot 730 9 1.01 (0.52-1.96) 1.07 (0.53-2.16) 3 0.50 (0.16-1.56) 0.56 (0.17-1.84)
Esophageal atresia 648 7 0.98 (0.46-2.08) 1.10 (0.50-2.42) 2 0.38 (0.09-1.54) 0.49 (0.12-2.05)
Gastroschisis 615 19 1.64 (1.02-2.63) 2.02 (1.13-3.61) 5 0.98 (0.40-2.40) 0.86 (0.31-2.36)
Omphalocele 467 9 1.56 (0.80-3.05) 1.35 (0.70-2.62) 5 1.42 (0.58-3.45) 1.21 (0.48-3.08)
Hypospadias 5,097 76 1.03 (0.80-1.32) 1.38 (0.91-2.10) 43 1.01 (0.72-1.41) 1.51 (0.84-2.70)
Anal atresia/stenosis 772 18 1.78 (1.11-2.87) 2.11 (1.26-3.54) 12 1.95 (1.09-3.48) 2.77 (1.48-5.17)
Analyses were adjusted for center and maternal age.
Boldface denotes associations significant at the 5% level.
CHD, Congenital heart defect.
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TABLE E5. Adjustment for use of systemic steroids
Control group
Inhaled b2-agonists, ATC code R03AC Inhaled corticosteroids, ATC code R03BA
Nonchromosomal Chromosomal Nonchromosomal Chromosomal
Controls 43,824 9,578 43,824 9,578
Exposed controls 592 97 349 51
Total
cases
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Any signal anomaly 1,6803 264 1.24 (1.05-1.46) 1.46 (1.10-1.93) 133 0.85 (0.68-1.07) 1.01 (0.68-1.49)
Spina bifida 1,194 17 1.11 (0.64-1.92) 1.30 (0.70-2.43) 7 0.69 (0.30-1.59) 0.68 (0.26-1.75)
Cleft palate 1,392 28 1.64 (1.06-2.53) 1.70 (1.03-2.80) 13 0.84 (0.45-1.58) 0.93 (0.45-1.92)
Cleft lip with/without
cleft palate
2,402 39 1.33 (0.91-1.93) 1.39 (0.87-2.21) 22 0.98 (0.60-1.61) 1.12 (0.60-2.09)
Severe CHD 4,738 64 1.20 (0.90-1.61) 1.23 (0.85-1.78) 27 0.61 (0.40-0.94) 0.97 (0.57-1.64)
Tetralogy of Fallot 730 9 1.28 (0.63-2.60) 1.36 (0.62-2.94) 3 0.43 (0.13-1.45) 0.46 (0.13-1.67)
Esophageal atresia 648 7 1.28 (0.58-2.82) 1.43 (0.62-3.32) 2 0.32 (0.07-1.38) 0.35 (0.08-1.64)
Gastroschisis 615 19 1.91 (1.13-3.24) 2.91 (1.47-5.76) 5 0.59 (0.22-1.60) 0.34 (0.10-1.13)
Omphalocele 467 9 1.50 (0.69-3.28) 1.37 (0.63-2.99) 5 1.06 (0.37-3.01) 0.95 (0.31-2.85)
Hypospadias 5,097 76 1.03 (0.78-1.38) 1.27 (0.79-2.05) 43 1.00 (0.68-1.46) 1.29 (0.67-2.50)
Anal atresia/stenosis 772 18 1.51 (0.85-2.69) 1.53 (0.79-2.94) 12 1.50 (0.74-3.03) 2.06 (0.94-4.51)
Analyses were adjusted for center, maternal age, and use of systemic steroids. Analyses of b2-agonists were adjusted for use of corticosteroids and vice versa.
CHD, Congenital heart defect.
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TABLE E6. Adjustment for period
Control group
Inhaled b2-agonists, ATC code R03AC Inhaled corticosteroids, ATC code R03BA
Nonchromosomal Chromosomal Nonchromosomal Chromosomal
Controls 43,824 9,578 43,824 9,578
Exposed controls 592 97 349 51
Total
cases
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Any signal anomaly 16,803 264 1.24 (1.05-1.46) 1.47 (1.11-1.95) 133 0.85 (0.68-1.07) 0.99 (0.67-1.46)
Spina bifida 1,194 17 0.90 (0.52-1.56) 1.39 (0.74-2.60) 7 1.45 (0.63-3.37) 0.67 (0.26-1.73)
Cleft palate 1,392 28 1.62 (1.05-2.51) 1.99 (1.20-3.29) 13 0.84 (0.44-1.57) 0.90 (0.44-1.87)
Cleft lip with/without
palate
2,402 39 1.34 (0.92-1.94) 1.59 (0.99-2.55) 22 0.98 (0.60-1.61) 1.13 (0.60-2.13)
severe CHD 4,738 64 1.21 (0.91-1.62) 1.40 (0.95-2.04) 27 0.61 (0.40-0.95) 0.73 (0.42-1.28)
Tetralogy of Fallot 730 9 1.31 (0.64-2.67) 1.58 (0.72-3.46) 3 0.42 (0.13-1.44) 0.46 (0.13-1.72)
Esophageal atresia 648 7 1.31 (0.59-2.90) 1.72 (0.73-4.03) 2 0.32 (0.07-1.40) 0.37 (0.08-1.76)
Gastroschisis 615 19 1.90 (1.12-3.22) 3.04 (1.53-6.06) 5 0.60 (0.22-1.62) 0.33 (0.10-1.11)
Omphalocele 467 9 1.53 (0.69-3.35) 1.76 (0.74-4.20) 5 1.10 (0.38-3.13) 1.26 (0.39-4.05)
Hypospadias 5,097 76 1.04 (0.78-1.39) 1.39 (0.86-2.25) 43 0.94 (0.64-1.37) 1.21 (0.62-2.36)
Anorectal atresia/stenosis 772 18 1.47 (0.83-2.63) 1.78 (0.92-3.45) 12 1.52 (0.75-3.07) 1.64 (0.72-3.73)
Analyses were adjusted for center, maternal age, and period (5-year intervals). Analyses of b2-agonists were adjusted for use of corticosteroids and vice versa.
CHD, Congenital heart defect.
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TABLE E7. Isolated anomalies
Control group
Inhaled b2-agonists, ATC code R03AC Inhaled corticosteroids, ATC code R03BA
Nonchromosomal Chromosomal Nonchromosomal Chromosomal
Controls 33,237 9,578 33,237 9,578
Exposed controls 452 97 292 51
Total
cases
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Exposed
cases
Adjusted OR
(95% CI)
Adjusted OR
(95% CI)
Any signal anomaly 11,678 166 1.12 (0.91-1.37) 1.22 (0.89-1.67) 95 0.85 (0.65-1.11) 0.96 (0.63-1.46)
Spina bifida 771 8 0.73 (0.32-1.64) 0.75 (0.31-1.81) 5 0.96 (0.35-2.67) 0.98 (0.32-3.01)
Cleft palate 886 17 1.73 (0.99-3.01) 1.52 (0.82-2.81) 7 0.60 (0.26-1.40) 0.66 (0.26-1.68)
Cleft lip with/without
palate
1,690 27 1.41 (0.89-2.23) 1.37 (0.80-2.34) 16 0.87 (0.48-1.57) 0.97 (0.48-1.96)
Severe CHD 3,436 38 0.95 (0.65-1.38) 0.97 (0.64-1.49) 22 0.72 (0.44-1.18) 1.14 (0.65-2.00)
Tetralogy of Fallot 515 5 1.09 (0.42-2.84) 1.00 (0.37-2.73) 2 0.42 (0.09-1.85) 0.48 (0.10-2.27)
Esophageal atresia 274 3 1.72 (0.51-5.84) 1.49 (0.42-5.25) 1 0.32 (0.04-2.62) 0.39 (0.05-3.31)
Gastroschisis 416 14 1.89 (1.01-3.54) 2.58 (1.18-5.64) 4 0.60 (0.19-1.88) 0.36 (0.10-1.34)
Omphalocele 207 2 0.54 (0.10-2.86) 0.51 (0.13-2.01) 3 2.65 (0.68-10.35) 1.78 (0.44-7.17)
Hypospadias 3,747 54 0.97 (0.69-1.38) 1.15 (0.69-1.93) 35 1.03 (0.67-1.58) 1.29 (0.65-2.57)
Anorectal atresia/stenosis 265 4 1.15 (0.35-3.73) 0.80 (0.23-2.76) 3 1.21 (0.31-4.68) 2.73 (0.78-9.58)
Analyses were adjusted for center, maternal age, and period (5-year intervals). Analyses of b2-agonists were adjusted for use of corticosteroids and vice versa. Cases and
nonchromosomal controls were restricted to isolated anomalies.
CHD, Congenital heart defect.
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